| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Seyyede Fatemeh Shams, Hossein Ayatollahi, Mohammad Hadi Sadeghian, Monavar Afzalaghaee, Sepideh Shakeri, Ehsan Yazdandoust, Maryam Sheikhi, Nafiseh Amini, Samane Bakhshi, Afsane Bahram. Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran. Iranian journal of pathology. vol 13. issue 4. 2020-09-29. PMID:30774677. |
janus kinase 2 (jak2) and myeloproliferative leukemia (mpl) mutations are confirmatory indicators for myeloproliferative neoplasm (mpn). |
2020-09-29 |
2023-08-13 |
Not clear |
| Seyyede Fatemeh Shams, Hossein Ayatollahi, Mohammad Hadi Sadeghian, Monavar Afzalaghaee, Sepideh Shakeri, Ehsan Yazdandoust, Maryam Sheikhi, Nafiseh Amini, Samane Bakhshi, Afsane Bahram. Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran. Iranian journal of pathology. vol 13. issue 4. 2020-09-29. PMID:30774677. |
the current study was performed to determine the frequency of mpl mutation in mpn patients without jak2 mutation, in order to assign mpl mutation frequency in north-east of iran. |
2020-09-29 |
2023-08-13 |
Not clear |
| Stephan Bartels, Muhammad Faisal, Guntram Büsche, Jerome Schlue, Britta Hasemeier, Elisa Schipper, Julia Vogtmann, Lina Westphal, Ulrich Lehmann, Hans Kreip. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. vol 34. issue 5. 2020-09-29. PMID:31776465. |
age-related clonal hematopoiesis (arch/chip) is a frequent finding in the elderly and combinations with mpn driver mutations (jak2, mpl, and calr) have been described. |
2020-09-29 |
2023-08-13 |
Not clear |
| Nicolas Chatain, Steffen Koschmieder, Edgar Jos. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Cancers. vol 12. issue 8. 2020-09-28. PMID:32806517. |
in nearly all patients with ph-neg mpn, mutations in the genes encoding janus kinase 2 (jak2), calreticulin (calr), or the thrombopoietin receptor (mpl) can be detected and, together with additional mutations in epigenetic modifier genes, these genetic aberrations contribute to the clonal expansion of the cells. |
2020-09-28 |
2023-08-13 |
mouse |
| Nami Masubuchi, Marito Araki, Yinjie Yang, Erina Hayashi, Misa Imai, Yoko Edahiro, Yumi Hironaka, Yoshihisa Mizukami, Yoshihiko Kihara, Hiraku Takei, Mai Nudejima, Masato Koike, Akimichi Ohsaka, Norio Komats. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia. vol 34. issue 2. 2020-08-04. PMID:31462733. |
based on these findings, we propose a model in which mutant calr induces mpl activation on the cell surface to promote mpn development. |
2020-08-04 |
2023-08-13 |
Not clear |
| Jessica L Bridgford, Su Min Lee, Christine M M Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F Rubin, Mario Cazzola, Alessandro M Vannucchi, Andrew J Brooks, Matthew E Call, Melissa J Cal. Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood. vol 135. issue 4. 2020-06-29. PMID:31697803. |
we found examples of both of these categories in published and previously unpublished mpl exon 10 sequencing data from mpn patients, demonstrating that some, if not all, of the new mutations reported here represent likely drivers or modifiers of myeloproliferative disease. |
2020-06-29 |
2023-08-13 |
human |
| Waihay J Wong, Michele Baltay, Annaliese Getz, Kit Fuhrman, Jon C Aster, Robert P Hasserjian, Olga Pozdnyakov. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PloS one. vol 14. issue 5. 2020-01-21. PMID:31071164. |
the philadelphia chromosome-negative myeloproliferative neoplasms (mpn) share similar molecular characteristics in that they frequently harbor hotspot mutations in jak2, calr or mpl, leading to activated jak/stat signaling. |
2020-01-21 |
2023-08-13 |
Not clear |
| Elodie Pronier, Paolo Cifani, Tiffany R Merlinsky, Katharine Barr Berman, Amritha Varshini Hanasoge Somasundara, Raajit K Rampal, John LaCava, Karen E Wei, Friederike Pastore, Jesper Lv Maag, Jane Park, Richard Koche, Alex Kentsis, Ross L Levin. Targeting the CALR interactome in myeloproliferative neoplasms. JCI insight. vol 3. issue 22. 2019-11-12. PMID:30429377. |
mutations in the er chaperone calreticulin (calr) are common in myeloproliferative neoplasm (mpn) patients, activate the thrombopoietin receptor (mpl), and mediate constitutive jak/stat signaling. |
2019-11-12 |
2023-08-13 |
Not clear |
| Hans Michael Kvasnick. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria. [Rinsho ketsueki] The Japanese journal of clinical hematology. vol 60. issue 9. 2019-10-25. PMID:31597840. |
therefore, bm remains the central diagnostic platform and is essential for distinguishing et from pre-fibrotic pmf and diagnosing cases which do not express jak2, mpl or calr ('wild-type' or 'triple-negative' mpn). |
2019-10-25 |
2023-08-13 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. American journal of hematology. vol 93. issue 12. 2019-08-19. PMID:30039550. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations; additional disease features include bone marrow stromal reaction including reticulin fibrosis, abnormal cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (emh), constitutional symptoms, cachexia, leukemic progression, and shortened survival. |
2019-08-19 |
2023-08-13 |
Not clear |
| Marito Araki, Yinjie Yang, Misa Imai, Yoshihisa Mizukami, Yoshihiko Kihara, Yoshitaka Sunami, Nami Masubuchi, Yoko Edahiro, Yumi Hironaka, Satoshi Osaga, Akimichi Ohsaka, Norio Komats. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia. vol 33. issue 1. 2019-05-30. PMID:29946189. |
since association with mpl is required for the oncogenicity of mutant calr, we propose a model in which the constitutive activation of the mpl downstream pathway by mutant calr multimers induces the development of mpn. |
2019-05-30 |
2023-08-13 |
Not clear |
| Sérgio Ferreira Cristina, Blanca Polo, João F Lacerd. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Seminars in hematology. vol 55. issue 4. 2019-05-07. PMID:30502850. |
the discovery of somatic mutations in mpn, namely jak2 v617f, jak2 exon 12, mpl, and calr mutations, has permitted a more specific approach to diagnosis and treatment. |
2019-05-07 |
2023-08-13 |
Not clear |
| Makoto Ikejir. [JAK2, CALR]. Rinsho byori. The Japanese journal of clinical pathology. vol 65. issue 1. 2019-04-26. PMID:30695513. |
subsequently, jak2 exon 12 mutation, mpl gene mutation, and calr gene mutation were detected in 2013, and it was revealed that in almost all cases of bcr/abl- negative mpn, any gene mutation could be involved as a driver gene mutation. |
2019-04-26 |
2023-08-13 |
Not clear |
| Shannon Elf, Nouran S Abdelfattah, April J Baral, Danielle Beeson, Jeanne F Rivera, Amy Ko, Natalie Florescu, Gabriel Birrane, Edwin Chen, Ann Mullall. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. vol 131. issue 7. 2019-01-30. PMID:29288169. |
defining the requirements for the pathogenic interaction between mutant calreticulin and mpl in mpn. |
2019-01-30 |
2023-08-13 |
Not clear |
| Tao Lang, Yuling Nie, Zengsheng Wang, Qin Huang, Li An, Yichun Wang, Guzailinuer Wufuer, Aziguli Maimaiti, Ling Fu, Yan Li, Xiaoyan Zhang, Aihemaitijiang Aisimutula, Xiaomin Wang, Lin Zhu, Hong Liu, Min Ma. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics. The Journal of international medical research. vol 46. issue 11. 2019-01-14. PMID:30084272. |
this study explored the relationship between mutations in the janus kinase 2 gene ( jak2), mpl, and the calreticulin gene ( calr) in uygur and han chinese patients with bcr-abl fusion gene-negative mpn and corresponding clinical features. |
2019-01-14 |
2023-08-13 |
Not clear |
| Zhi-Peng He, Yong W. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review]. Zhongguo shi yan xue ye xue za zhi. vol 26. issue 2. 2018-10-25. PMID:29665937. |
the mutations of jak2, calr and mpl genes are involved in the pathogenesis of mpn that provided a more complete molecular diagnostic standard for mpn. |
2018-10-25 |
2023-08-13 |
Not clear |
| Jennifer M O'Sullivan, Claire N Harriso. Myelofibrosis: clinicopathologic features, prognosis, and management. Clinical advances in hematology & oncology : H&O. vol 16. issue 2. 2018-09-26. PMID:29741513. |
considerable advancements have been made in the understanding of mpn pathogenesis, in particular recognition of the driver mutations jak2 v617f, calr, and mpl, which has led to the development of ruxolitinib, an inhibitor of janus kinase 1 (jak1) and jak2 that has transformed therapy for myelofibrosis. |
2018-09-26 |
2023-08-13 |
Not clear |
| Mara Jorgelina Ojeda, Irma Margarita Bragós, Karina Lucrecia Calvo, Gladis Marcela Williams, María Magdalena Carbonell, Arianna Flavia Pratt. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands). vol 23. issue 4. 2018-09-05. PMID:28990497. |
to establish the frequency of jak2, mpl and calr mutations in argentinean patients with bcr-abl1-negative myeloproliferative neoplasms (mpn) and to compare their clinical and haematological features. |
2018-09-05 |
2023-08-13 |
Not clear |
| Hany Sakr, Kelli Clark Schneider, Gurunathan Murugesan, Juraj Bodo, Eric D Hsi, James R Coo. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. Applied immunohistochemistry & molecular morphology : AIMM. vol 26. issue 2. 2018-08-24. PMID:27258562. |
analysis of 30 bcr/abl1-negative, nonpolycythemia vera mpn identified 15 (50%) with jak2 v617f, 2 with mpl mutations (7%), and 8 with calr mutations (27%). |
2018-08-24 |
2023-08-13 |
Not clear |
| Chih-Cheng Chen, Chia-Chen Hsu, Cih-En Huang, Yi-Yang Chen, Jrhau Lung, Hsing-Ying Ho, Chian-Pei Li, Jiann-Der Le. Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke. Current neurovascular research. vol 14. issue 3. 2018-05-14. PMID:28625126. |
somatic mutations of janus kinase 2 (jak2v617f), calreticulin (calr), and myeloproliferative leukemia virus oncogene (mpl) are the major clonal molecules that drive the pathogenesis of myeloproliferative neoplasms (mpn). |
2018-05-14 |
2023-08-13 |
Not clear |